A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

Phase 3 Completed NCT03671148

Condition	Psoriatic Arthritis
Phase	Phase 3
Sponsor	AbbVie
Status	Completed
Enrollment	444 participants
Interventions	Risankizumab
Start date	Mar 7, 2019
Completion date	Jun 22, 2020
Results posted	Mar 2, 2022

Summary

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24

Baseline and Week 24 · percentage of participants

Placebo	26.5 percentage of participants
Risankizumab	51.3 percentage of participants

p-value	<0.001
Response Rate Difference	24.5 (95% CI 15.9–33.0)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With A — UCB Biopharma SRL
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский